These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 8980774

  • 1. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
    Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, Freimuth WW.
    Antimicrob Agents Chemother; 1997 Jan; 41(1):169-74. PubMed ID: 8980774
    [Abstract] [Full Text] [Related]

  • 2. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infections.
    Morse GD, Fischl MA, Shelton MJ, Borin MT, Driver MR, DeRemer M, Lee K, Wajszczuk CP.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):767-71. PubMed ID: 8851608
    [Abstract] [Full Text] [Related]

  • 3. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
    Davey RT, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL, Lane HC.
    Antimicrob Agents Chemother; 1996 Jul; 40(7):1657-64. PubMed ID: 8807058
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
    Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA.
    Antiviral Res; 1997 Jun; 35(1):53-63. PubMed ID: 9224961
    [Abstract] [Full Text] [Related]

  • 5. Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.
    Morse GD, Cohn SE, Shelton MJ, Greisberger C, Cox SR, Della-Coletta AA, Freimuth WW, Reichman RC.
    Clin Drug Investig; 2003 Jun; 23(5):323-8. PubMed ID: 17535044
    [Abstract] [Full Text] [Related]

  • 6. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
    Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL.
    Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
    Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M.
    J Acquir Immune Defic Syndr; 1999 Aug 01; 21(4):281-92. PubMed ID: 10428106
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
    Chong KT, Pagano PJ.
    Antiviral Res; 1997 Mar 01; 34(1):51-63. PubMed ID: 9107385
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers.
    Ferry JJ, Herman BD, Carel BJ, Carlson GF, Batts DH.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul 01; 18(3):252-9. PubMed ID: 9665503
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.
    Pediatr Infect Dis J; 2005 Jun 01; 24(6):503-9. PubMed ID: 15933559
    [Abstract] [Full Text] [Related]

  • 11. FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
    Mascolini M.
    AIDS Treat News; 1996 Dec 06; (No 260):3-5. PubMed ID: 11364022
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
    Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW.
    Clin Pharmacol Ther; 1997 May 06; 61(5):544-53. PubMed ID: 9164416
    [Abstract] [Full Text] [Related]

  • 13. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
    Wang LH, Chittick GE, McDowell JA.
    Antimicrob Agents Chemother; 1999 Jul 06; 43(7):1708-15. PubMed ID: 10390227
    [Abstract] [Full Text] [Related]

  • 14. Effects of didanosine formulations on the pharmacokinetics of amprenavir.
    Shelton MJ, Giovanniello AA, Cloen D, Berenson CS, Keil K, DiFrancesco R, Hewitt RG.
    Pharmacotherapy; 2003 Jul 06; 23(7):835-42. PubMed ID: 12885096
    [Abstract] [Full Text] [Related]

  • 15. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine.
    Shelton MJ, Adams JM, Hewitt RG, Steinwandel C, DeRemer M, Cousins S, Morse GD.
    Pharmacotherapy; 1997 Jul 06; 17(3):438-44. PubMed ID: 9165548
    [Abstract] [Full Text] [Related]

  • 16. [A new AIDS drug in evaluation].
    Fortschr Med; 1993 Aug 30; 111(24):12. PubMed ID: 7691696
    [No Abstract] [Full Text] [Related]

  • 17. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb 01; 14(2):136-44. PubMed ID: 9052722
    [Abstract] [Full Text] [Related]

  • 18. Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats.
    Chang M, Sood VK, Wilson GJ, Kloosterman DA, Sanders PE, Hauer MJ, Fagerness PE.
    Drug Metab Dispos; 1997 Feb 01; 25(2):228-42. PubMed ID: 9029054
    [Abstract] [Full Text] [Related]

  • 19. Effect of high-dose oral ganciclovir on didanosine disposition in human immunodeficiency virus (HIV)-positive patients.
    Jung D, Griffy K, Dorr A, Raschke R, Tarnowski TL, Hulse J, Kates RE.
    J Clin Pharmacol; 1998 Nov 01; 38(11):1057-62. PubMed ID: 9824788
    [Abstract] [Full Text] [Related]

  • 20. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
    Borin MT, Cox SR, Herman BD, Carel BJ, Anderson RD, Freimuth WW.
    Antimicrob Agents Chemother; 1997 Sep 01; 41(9):1892-7. PubMed ID: 9303380
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.